Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine in HFpEF
NCT05637398Phase 2Completed
- Sponsor
- Sechenov First Moscow State Medical University
- Start
- Dec 2022
- Primary completion
- Sep 2025
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised trial of colchicine in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Sechenov First Moscow State Medical University. Primary endpoints: Soluble suppression of tumourigenicity 2 at 12 weeks and High-sensitivity C-reactive protein at 12 weeks. Started Dec 2022; status: completed.
02
Drugs
colchicine
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05637398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05637398.